Boosting Therapeutic Substitution Rests With Physician Education, HHS Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Issue brief by the Office of the Assistant Secretary for Planning and Evaluation cites cost-savings potential of increasing substitution of brand drugs with generics that are not therapeutically equivalent but carry the same indication.
You may also be interested in...
ANDAs For Narrow Therapeutic Index Drugs May Need Crossover Studies
FDA’s challenges in creating a more specific definition of narrow therapeutic index drugs were on clear display at the most recent advisory committee meeting on the topic: There’s wide support for the project, but equally broad concern that it needs to be more carefully tailored.
ANDAs For Narrow Therapeutic Index Drugs May Need Crossover Studies
FDA’s challenges in creating a more specific definition of narrow therapeutic index drugs were on clear display at the most recent advisory committee meeting on the topic: There’s wide support for the project, but equally broad concern that it needs to be more carefully tailored.
FDA's Woodcock Expresses Concern Not All Generics Are Equivalent, But OGD May Have Solution
It didn't seem like deliberate choice to play good cop-bad cop, but Acting Office of Generic Drugs Director Keith Webber and Center for Drug Evaluation and Research Director Janet Woodcock offered a near textbook version of it at the recent Generic Pharmaceutical Association Fall Technical Conference.